Adaptive Biotechnologies Corporation (ADPT)
| Market Cap | 4.53B +68.7% |
| Revenue (ttm) | 298.01M +17.9% |
| Net Income | -70.52M |
| EPS | -0.45 |
| Shares Out | 161.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,333,526 |
| Open | 26.98 |
| Previous Close | 26.83 |
| Day's Range | 26.54 - 28.27 |
| 52-Week Range | 12.00 - 30.74 |
| Beta | 2.15 |
| Analysts | Strong Buy |
| Price Target | 30.21 (+7.97%) |
| Earnings Date | Nov 4, 2026 |
About ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minima... [Read more]
Financial Performance
In 2025, Adaptive Biotechnologies's revenue was $276.98 million, an increase of 54.77% compared to the previous year's $178.96 million. Losses were -$59.50 million, -62.69% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ADPT stock is "Strong Buy." The 12-month stock price target is $30.21, which is an increase of 7.97% from the latest price.
News
Adaptive Biotechnologies raises FY26 revenue view to $276M-$286M
Prior guidance for FY26 revenue was from $268M-$278M. Consensus for FY26 total revenue is $293.25M. The company raised its full-year MRD business outlook, representing annual growth of 30% to 35%,…
Adaptive Biotechnologies reports Q3 EPS 2c, consensus (10c)
Reports Q3 revenue $83.9M, consensus $71.6M. Core MRD revenue increased 28% year-over-year to $72.6M, while clonoSEQ test volume grew 46% to 39,587 tests. “Adaptive achieved total company profitabilit...
Adaptive Biotechnologies Earnings Call Transcript: Q3 2026
Q3 delivered positive Adjusted EBITDA and GAAP net income alongside strong MRD growth, prompting higher FY2026 MRD revenue guidance. Updated myeloma guidance and a cure definition support expanding clinical use and pharma demand, while reimbursement and ASP timing remain key uncertainties.
Adaptive Biotechnologies Earnings release: Q3 2026
Adaptive Biotechnologies released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Adaptive Biotechnologies Quarterly report: Q3 2026
Adaptive Biotechnologies has published its Q3 2026 quarterly earnings report on November 4, 2026.
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the geneti...
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Adaptive Biotechnologies price target raised to $30 from $27 at JPMorgan
JPMorgan raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $30 from $27 and keeps an Overweight rating on the shares. The firm updated models in the life science…
Adaptive Biotechnologies price target raised to $32 from $28 at TD Cowen
TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $32 from $28 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics…
Adaptive Biotechnologies price target raised to $27 from $22 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $27 from $22 and keeps an Equal Weight rating on the shares as the firm refreshed models in…
Adaptive Biotechnologies price target raised to $32 from $25 at Guggenheim
Guggenheim raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $32 from $25 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for…
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Evie Koslosky initiated coverage of Adaptive Biotechnologies (ADPT) with a Buy rating and $35 price target The company has established itself as “the leader” in next-generation s...
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sys...
Adaptive Biotechnologies price target raised to $34 from $25 at BTIG
BTIG raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $34 from $25 and keeps a Buy rating on the shares. The firm notes that the NCCN update –…
Adaptive Biotechnologies reports update to NCCN guidelines for Multiple Myeloma
Adaptive Biotechnologies (ADPT) highlighted updates to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Multiple Myeloma that further establish highly sensitive m...
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10 -6 sensitiv...
Adaptive Biotechnologies Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
NCCN guidelines now specifically name clonoSEQ for MRD testing in multiple myeloma, boosting clinical adoption and expanding the addressable market. Strong volume growth, increased use of blood-based testing, and robust pharma momentum support a positive financial outlook, while a planned business separation aims to unlock further value.
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sys...
Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science
Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode
Adaptive Biotechnologies price target raised to $27.50 from $20 at Piper Sandler
Piper Sandler raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $27.50 from $20 following quarterly results. The firm keeps an Overweight rating on the shares. Published first on…
Adaptive Biotechnologies price target raised to $27 from $25 at JPMorgan
JPMorgan raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $27 from $25 and keeps an Overweight rating on the shares.
Adaptive Biotechnologies price target raised to $22 from $20 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $22 from $20 and keeps an Equal Weight rating on the shares. Adaptive “exceeded the…
Adaptive Biotechnologies price target raised to $25 from $24 at BTIG
BTIG raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $25 from $24 and keeps a Buy rating on the shares. The company delivered another strong beat and raise…
Adaptive Biotechnologies price target raised to $28 from $25 at TD Cowen
TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $28 from $25 and keeps a Buy rating on the shares. The firm said they delivered another solid…
Adaptive Biotechnologies price target raised to $25 from $22 at Guggenheim
Guggenheim raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $25 from $22 and keeps a Buy rating on the shares after Adaptive “beat again” on volumes. Even with…